E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
HUTCHMED’s sovleplenib is under regulatory review in China for primary immune thrombocytopenia (ITP) and warm antibody autoimmune haemolytic anaemia.
imphoenix82
Developed by Lakefront in collaboration with Gilead Sciences, gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the US FDA for the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
